Intranasal vaccination with killed Leishmania amazonensis promastigotes antigen (LaAg) associated with CAF01 adjuvant induces partial protection in BALB/c mice challenged with Leishmania (infantum) chagasi

The CAF01 adjuvant has previously been shown to be safe for human use and to be a potent adjuvant for several vaccine antigens. In the present work, we sought to optimize the Leishmania amazonensis antigens (LaAg) intranasal vaccine in an attempt to enhance the protective immune responses against Le...

Full description

Saved in:
Bibliographic Details
Published in:Parasitology 2015-11, Vol.142 (13), p.1640-1646
Main Authors: LEAL, JANINE MIRANDA, MOSQUINI, MARCELLE, COVRE, LUCIANA POLACO, STAGMILLER, NATALY PESCINALLI, RODRIGUES, RODRIGO RIBEIRO, CHRISTENSEN, DENNIS, GUEDES, HERBERT LEONEL DE MATOS, ROSSI-BERGMANN, BARTIRA, GOMES, DANIEL CLÁUDIO DE OLIVIERA
Format: Article
Language:English
Subjects:
Adjuvants, Immunologic - administration & dosage
Administration, Intranasal
Animals
Antibodies, Protozoan - blood
Antigens, Protozoan - immunology
Cytokines - biosynthesis
Epitopes
Female
Immunity, Cellular
Immunoglobulin G - blood
Leishmania amazonensis
Leishmania infantum
Leishmania infantum - immunology
Leishmania mexicana - immunology
Leishmaniasis, Visceral - prevention & control
Liver - parasitology
Mice
Mice, Inbred BALB C
Nitrites - metabolism
Parasites
Protozoan Vaccines - administration & dosage
Spleen - cytology
Spleen - immunology
Spleen - parasitology
Vaccines
Vaccines, Inactivated - administration & dosage
Vector-borne diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The CAF01 adjuvant has previously been shown to be safe for human use and to be a potent adjuvant for several vaccine antigens. In the present work, we sought to optimize the Leishmania amazonensis antigens (LaAg) intranasal vaccine in an attempt to enhance the protective immune responses against Leishmania (infantum) chagasi by using the CAF01 association. LaAg/CAF01 vaccinated mice that were challenged 15 days after booster dose with L. (infantum) chagasi showed a significant reduction in their parasite burden in both the spleen and liver, which is associated with an increase in specific production of IFN-γ and nitrite, and a decrease in IL-4 production. In addition, LaAg/CAF01 intranasal delivery was able to increase lymphoproliferative immune responses after parasite antigen recall. These results suggest the feasibility of using the intranasal route for the delivery of crude antigens and of a human-compatible adjuvant against visceral leishmaniasis.
ISSN:0031-1820
1469-8161
1469-8161
DOI:10.1017/S0031182015001250